CANF ▲ +39.4% - Can-Fite BioPharma Ltd. $CANF - Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study Can-Fite BioPharma shares surged 39.4% after the company reported longer-than-anticipated overall survival results from its ongoing Phase III pivotal trial in liver cancer, a milestone that could strengthen the drug candidate's regulatory prospects. The extended survival data in a late-stage study typically signals improved efficacy and increases the likelihood of eventual approval, driving investor optimism in the biotech stock. 02-SEP-2026 07:02 AM ET